Concepts (122)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| HIV Infections | 5 | 2024 | 77 | 1.230 |
Why?
|
| Cytomegalovirus Infections | 2 | 2015 | 2 | 0.920 |
Why?
|
| Kidney Transplantation | 3 | 2024 | 6 | 0.890 |
Why?
|
| Staphylococcal Infections | 2 | 2016 | 7 | 0.860 |
Why?
|
| Humans | 15 | 2025 | 1907 | 0.710 |
Why?
|
| Antifungal Agents | 2 | 2018 | 3 | 0.670 |
Why?
|
| Retrospective Studies | 6 | 2021 | 102 | 0.650 |
Why?
|
| Adult | 7 | 2021 | 554 | 0.600 |
Why?
|
| Transplant Recipients | 2 | 2018 | 3 | 0.590 |
Why?
|
| Male | 9 | 2025 | 1055 | 0.570 |
Why?
|
| Cryptococcosis | 1 | 2018 | 1 | 0.560 |
Why?
|
| Organ Transplantation | 1 | 2018 | 2 | 0.560 |
Why?
|
| Population Health | 1 | 2018 | 2 | 0.560 |
Why?
|
| Middle Aged | 7 | 2024 | 494 | 0.560 |
Why?
|
| Dermatomycoses | 1 | 2017 | 1 | 0.530 |
Why?
|
| Opportunistic Infections | 1 | 2017 | 1 | 0.530 |
Why?
|
| Ustilaginales | 1 | 2017 | 1 | 0.530 |
Why?
|
| Yeasts | 1 | 2017 | 1 | 0.530 |
Why?
|
| Fungemia | 1 | 2017 | 1 | 0.530 |
Why?
|
| Exanthema | 1 | 2017 | 5 | 0.530 |
Why?
|
| Graft Rejection | 2 | 2024 | 4 | 0.530 |
Why?
|
| Endocarditis, Bacterial | 1 | 2016 | 1 | 0.510 |
Why?
|
| Staphylococcus lugdunensis | 1 | 2016 | 1 | 0.510 |
Why?
|
| Bacteremia | 1 | 2016 | 4 | 0.510 |
Why?
|
| Inpatients | 1 | 2015 | 3 | 0.470 |
Why?
|
| Renal Insufficiency | 1 | 2014 | 2 | 0.450 |
Why?
|
| Heart Transplantation | 1 | 2014 | 2 | 0.450 |
Why?
|
| United States | 5 | 2022 | 157 | 0.450 |
Why?
|
| Female | 7 | 2025 | 984 | 0.420 |
Why?
|
| Aged | 4 | 2021 | 418 | 0.380 |
Why?
|
| Young Adult | 4 | 2021 | 143 | 0.380 |
Why?
|
| Tissue and Organ Procurement | 2 | 2024 | 3 | 0.380 |
Why?
|
| Lemierre Syndrome | 1 | 2011 | 1 | 0.350 |
Why?
|
| Methicillin-Resistant Staphylococcus aureus | 1 | 2011 | 4 | 0.350 |
Why?
|
| Tissue Donors | 3 | 2024 | 7 | 0.310 |
Why?
|
| Severity of Illness Index | 2 | 2021 | 59 | 0.300 |
Why?
|
| Aged, 80 and over | 3 | 2021 | 210 | 0.300 |
Why?
|
| Immunocompromised Host | 2 | 2017 | 4 | 0.260 |
Why?
|
| Trees | 1 | 2025 | 1 | 0.240 |
Why?
|
| Health Services Accessibility | 1 | 2025 | 7 | 0.230 |
Why?
|
| Asthma | 1 | 2025 | 7 | 0.230 |
Why?
|
| Kidney Failure, Chronic | 1 | 2024 | 5 | 0.220 |
Why?
|
| HIV-1 | 1 | 2022 | 40 | 0.190 |
Why?
|
| Adolescent | 2 | 2025 | 188 | 0.190 |
Why?
|
| Liver Transplantation | 1 | 2021 | 1 | 0.180 |
Why?
|
| Hepatitis C | 1 | 2021 | 4 | 0.180 |
Why?
|
| Forecasting | 1 | 2021 | 9 | 0.180 |
Why?
|
| Databases, Factual | 1 | 2021 | 9 | 0.180 |
Why?
|
| Hospitalization | 1 | 2021 | 22 | 0.170 |
Why?
|
| Models, Biological | 1 | 2021 | 99 | 0.170 |
Why?
|
| Cohort Studies | 2 | 2022 | 108 | 0.170 |
Why?
|
| Comorbidity | 2 | 2021 | 27 | 0.160 |
Why?
|
| Follow-Up Studies | 2 | 2021 | 69 | 0.160 |
Why?
|
| Risk Factors | 2 | 2021 | 143 | 0.150 |
Why?
|
| Meningitis, Cryptococcal | 1 | 2018 | 1 | 0.140 |
Why?
|
| Cryptococcus | 1 | 2017 | 1 | 0.130 |
Why?
|
| Cytarabine | 1 | 2017 | 1 | 0.130 |
Why?
|
| Saccharomyces | 1 | 2017 | 1 | 0.130 |
Why?
|
| Trichosporon | 1 | 2017 | 1 | 0.130 |
Why?
|
| Vidarabine | 1 | 2017 | 1 | 0.130 |
Why?
|
| Idarubicin | 1 | 2017 | 1 | 0.130 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 2017 | 1 | 0.130 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 1 | 2017 | 1 | 0.130 |
Why?
|
| Salvage Therapy | 1 | 2017 | 1 | 0.130 |
Why?
|
| Echinocandins | 1 | 2017 | 1 | 0.130 |
Why?
|
| Lipopeptides | 1 | 2017 | 1 | 0.130 |
Why?
|
| Amphotericin B | 1 | 2017 | 2 | 0.130 |
Why?
|
| Voriconazole | 1 | 2017 | 2 | 0.130 |
Why?
|
| Biopsy | 1 | 2017 | 11 | 0.130 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2017 | 5 | 0.130 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2017 | 5 | 0.130 |
Why?
|
| Fever | 1 | 2017 | 10 | 0.130 |
Why?
|
| Lung Diseases, Fungal | 1 | 2016 | 1 | 0.130 |
Why?
|
| Paecilomyces | 1 | 2016 | 1 | 0.130 |
Why?
|
| Dyspnea | 1 | 2016 | 7 | 0.130 |
Why?
|
| Anti-Bacterial Agents | 1 | 2016 | 43 | 0.120 |
Why?
|
| Cytomegalovirus | 1 | 2014 | 1 | 0.110 |
Why?
|
| Incidence | 1 | 2014 | 45 | 0.110 |
Why?
|
| Time Factors | 1 | 2014 | 143 | 0.110 |
Why?
|
| Graft Survival | 2 | 2024 | 8 | 0.100 |
Why?
|
| Pneumonia, Staphylococcal | 1 | 2011 | 1 | 0.090 |
Why?
|
| Bacterial Typing Techniques | 1 | 2011 | 1 | 0.090 |
Why?
|
| Molecular Typing | 1 | 2011 | 1 | 0.090 |
Why?
|
| Cerebral Infarction | 1 | 2011 | 6 | 0.090 |
Why?
|
| Genotype | 1 | 2011 | 38 | 0.090 |
Why?
|
| Astacoidea | 1 | 2009 | 1 | 0.080 |
Why?
|
| Lung Diseases, Parasitic | 1 | 2009 | 1 | 0.080 |
Why?
|
| Paragonimiasis | 1 | 2009 | 1 | 0.080 |
Why?
|
| Shellfish | 1 | 2009 | 1 | 0.080 |
Why?
|
| Paragonimus westermani | 1 | 2009 | 1 | 0.080 |
Why?
|
| Residence Characteristics | 1 | 2025 | 7 | 0.060 |
Why?
|
| Socioeconomic Factors | 1 | 2025 | 16 | 0.060 |
Why?
|
| Disease Progression | 1 | 2025 | 43 | 0.060 |
Why?
|
| Chicago | 1 | 2025 | 56 | 0.060 |
Why?
|
| Child, Preschool | 1 | 2025 | 87 | 0.060 |
Why?
|
| Child | 1 | 2025 | 157 | 0.060 |
Why?
|
| Postoperative Complications | 1 | 2024 | 23 | 0.060 |
Why?
|
| Proviruses | 1 | 2022 | 1 | 0.050 |
Why?
|
| Virus Latency | 1 | 2022 | 3 | 0.050 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2022 | 6 | 0.050 |
Why?
|
| Data Accuracy | 1 | 2022 | 1 | 0.050 |
Why?
|
| Health Insurance Portability and Accountability Act | 1 | 2022 | 1 | 0.050 |
Why?
|
| Pilot Projects | 1 | 2021 | 29 | 0.050 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 2021 | 26 | 0.040 |
Why?
|
| Extracorporeal Membrane Oxygenation | 1 | 2021 | 6 | 0.040 |
Why?
|
| Prospective Studies | 1 | 2021 | 119 | 0.040 |
Why?
|
| Respiration, Artificial | 1 | 2021 | 13 | 0.040 |
Why?
|
| Pandemics | 1 | 2021 | 24 | 0.040 |
Why?
|
| Microbiological Techniques | 1 | 2016 | 1 | 0.030 |
Why?
|
| Radiography, Thoracic | 1 | 2016 | 2 | 0.030 |
Why?
|
| Bronchoscopy | 1 | 2016 | 4 | 0.030 |
Why?
|
| Microscopy | 1 | 2016 | 4 | 0.030 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2016 | 69 | 0.030 |
Why?
|
| Food Contamination | 1 | 2009 | 1 | 0.020 |
Why?
|
| Hemoptysis | 1 | 2009 | 1 | 0.020 |
Why?
|
| Praziquantel | 1 | 2009 | 1 | 0.020 |
Why?
|
| Food Parasitology | 1 | 2009 | 1 | 0.020 |
Why?
|
| Anthelmintics | 1 | 2009 | 3 | 0.020 |
Why?
|
| Missouri | 1 | 2009 | 3 | 0.020 |
Why?
|
| Tuberculosis | 1 | 2009 | 4 | 0.020 |
Why?
|
| Diagnosis, Differential | 1 | 2009 | 28 | 0.020 |
Why?
|
| Animals | 1 | 2009 | 748 | 0.020 |
Why?
|